Generate Biomedicines (NASDAQ:GENB) Trading Down 6.9% – Time to Sell?

Generate Biomedicines Inc (NASDAQ:GENB)’s share price fell 6.9% during trading on Monday . The stock traded as low as $12.83 and last traded at $12.80. 42,997 shares were traded during mid-day trading, a decline of 93% from the average session volume of 593,881 shares. The stock had previously closed at $13.75.

Wall Street Analyst Weigh In

GENB has been the subject of a number of research reports. The Goldman Sachs Group initiated coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $26.00 target price for the company. Cantor Fitzgerald began coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating on the stock. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Morgan Stanley began coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating and a $20.00 target price for the company. Finally, Guggenheim started coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $30.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

Generate Biomedicines Price Performance

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.